1. Introduction {#sec1-cancers-12-01515}
===============

Long-term survival of patients with non-small cell lung cancer (NSCLC) remains poor in spite of advances in therapies and refinement in multimodal approach \[[@B1-cancers-12-01515]\]. Operable patients have a better prognosis \[[@B1-cancers-12-01515]\], but a significant percentage of them require pneumonectomy which per se still carries important post-operative morbidity and mortality and modest 5-year survival. In a recently published study on 350 consecutive patients, we showed 30- and 90-day day mortalities of 9%, and 13%, respectively, and 5-year survival of 34% \[[@B2-cancers-12-01515]\], and these results are consistent with previous works of other teams \[[@B3-cancers-12-01515],[@B4-cancers-12-01515],[@B5-cancers-12-01515]\]. This stresses the need to better understand factors associated with short-term outcome, in order to optimize selection of patients for pneumonectomy. Respiratory complications are relatively frequent in pneumonectomy patients and are responsible for a significant percentage of operative mortality: Major respiratory complications occur in 10--20% of cases with progression to acute respiratory distress syndrome (ARDS) in approximately half of them \[[@B6-cancers-12-01515],[@B7-cancers-12-01515],[@B8-cancers-12-01515],[@B9-cancers-12-01515]\]. Patients with post-pneumonectomy ARDS have an extremely high mortality rate with figures ranging 50--90% \[[@B6-cancers-12-01515],[@B7-cancers-12-01515],[@B8-cancers-12-01515]\].

Some studies have addressed risk factors for post-operative respiratory failure and ARDS \[[@B6-cancers-12-01515],[@B7-cancers-12-01515],[@B8-cancers-12-01515],[@B10-cancers-12-01515],[@B11-cancers-12-01515],[@B12-cancers-12-01515]\]: Although the role of intra-operative non-protective ventilation (large tidal volume and increased airway pressures) and fluid administration (non-restriction) has been proved \[[@B10-cancers-12-01515],[@B13-cancers-12-01515]\], patient-related pre-operative factors, including respiratory function parameters, remain matter of debate because even studies with very large sample sizes sometimes failed to find significant correlations \[[@B11-cancers-12-01515],[@B14-cancers-12-01515]\]. A series dealing with non-selected consecutive patients requiring pneumonectomy, showed at univariate analysis a significant association of postoperative forced expiratory volume in 1 s (ppo-FEV~1~) with pulmonary complications, but multivariate analysis failed to prove the independent character of this association \[[@B13-cancers-12-01515]\]. In our recent monocentric study on 543 consecutive patients undergoing pneumonectomy for different indications, mainlyNSCLC, we reported that respiratory failure requiring invasive mechanical ventilation (IMV) and ARDS occurred in 16% and 11% of cases, respectively. At multivariate analysis, only right-side pneumonectomy and higher Charlson Comorbidity Index (CCI) were identified as independent risk factors for acute respiratory distress syndrome, whereas respiratory function parameters did not \[[@B15-cancers-12-01515]\].

A historical study showed that high mean pulmonary artery pressure (PAP) measured intraoperatively in patients undergoing pneumonectomy was associated with an increased incidence of cardiorespiratory complications and mortality \[[@B16-cancers-12-01515]\]. Assessment of systolic PAP may be carried out by echocardiography. Although this investigation is not part of recommended routine pre-operative work-up of pneumonectomy patients \[[@B17-cancers-12-01515]\], it is performed liberally in several centers and is mainly used to measure left ventricle ejection fraction. However, to our knowledge, echocardiographic assessment of PAP has not been suggested to predict respiratory complication and mortality of pneumonectomy patients. In lobectomy patients, the presence of high right ventricular systolic pressure measured at echocardiography did not correlate with outcome \[[@B18-cancers-12-01515]\].

A previous pilot study of our group on 161 consecutive patients undergoing pneumonectomy showed that normalized pulmonary artery diameter (NPAD) for body surface area (BSA) could be a predictor of postoperative respiratory failure and ARDS \[[@B19-cancers-12-01515]\]. Thus, we aimed at reporting our more mature experience on the topic evaluating, in a larger series of pneumonectomy patients, the impact of several pre-operative parameters, including NPAD and pulmonary artery diameter (PAD)/aorta diameter (AoD) ratio, on the occurrence of post-pneumonectomy respiratory failure and ARDS.

2. Results {#sec2-cancers-12-01515}
==========

Between January 2007 and December 2015, 294 patients treated by pneumonectomy for malignancy (289 NSCLC, 3 malignant pleural mesothelioma, 2 pulmonary metastasis from extra-pulmonary primary tumors) in our department had pre-operative thoracic CT scan. The main clinical-pathological characteristics of the study patients are summarized in [Table 1](#cancers-12-01515-t001){ref-type="table"}.

2.1. Morphometric Measurements {#sec2dot1-cancers-12-01515}
------------------------------

Results of morphometric measurements are reported in [Table 1](#cancers-12-01515-t001){ref-type="table"}. Median normalized diameter was 14 mm/m^2^ \[[@B13-cancers-12-01515],[@B14-cancers-12-01515],[@B15-cancers-12-01515],[@B16-cancers-12-01515]\]. Thus, 14 mm/m^2^ was used as cut-off to differentiate the subgroup of patients with increased NPAD.

2.2. Correlations between PAD, Morphometric Parameters, Clinical, and Laboratory Variables {#sec2dot2-cancers-12-01515}
------------------------------------------------------------------------------------------

Crude PAD was related with BSA (r = 0.315, *p* = 0.000082), providing argument for need of normalization by this parameter. Correlations between NPAD and PAD/AOD ratio with baseline morphometric, clinical, and laboratory variables are shown in [Table 2](#cancers-12-01515-t002){ref-type="table"}. Higher NPAD was associated with higher age (*p* = 0.0049) and lower BMI (*p* = 0.00024); a trend toward higher PAD was observed in women (*p* = 0.052). Of note, no relation was found between NPAD and respiratory function parameters.

2.3. Factors Associated with Short-Term Outcome: The Role of PAD {#sec2dot3-cancers-12-01515}
----------------------------------------------------------------

Postoperatively, 46 patients required re-do intubation and IMV and 30 of them had ARDS. Relations between patient's and tumor related factors with occurrence of respiratory failure requiring intubation or ARDS or death are reported in [Table 3](#cancers-12-01515-t003){ref-type="table"} and [Table 4](#cancers-12-01515-t004){ref-type="table"}.

Need of re-do intubation was related with higher age (*p* = 0.028), right-side of disease (*p* = 0.011), CCI \>5 (*p* = 0.00032), and higher NPAD (*p* = 0.010). Multivariate analysis (model including these significant factors) showed that CCI \>5 (*p* = 0.0009, OR 3.8 \[1.76--8.22\]), right side of pneumonectomy (*p* = 0.013, OR 2.37 \[1.20--4.71\]), and higher NPAD (*p* = 0.029, OR 2.16 \[1.08--4.33\]) were independent predictors of need of IMV ([Table 5](#cancers-12-01515-t005){ref-type="table"}).

Univariate analysis showed that transfer coefficient of the lung for carbon monoxide (KCO) was also associated with need of IMV. Because of KCO being assessed in 132 patients, another multivariate analysis model was performed including KCO together with age, side of disease, CCI, and normalized pulmonary artery diameter. In this model significance of KCO was lost whereas CCI, right side of pneumonectomy and NPAD maintained significance.

Occurrence of ARDS was associated with higher age (*p* = 0.020), right side of pneumonectomy (*p* = 0.043), CCI \>5 (*p* = 0.0043) and higher NPAD (*p* = 0.021). Multivariate analyses (model including the above quoted significant factors) showed that CCI \>5 (*p* = 0.018, OR 2.55 \[1.17--5.59\]) and higher NPAD (*p* = 0.028, OR = 2.52 \[1.10--5.77\]) were independently associated with occurrence of ARDS ([Table 5](#cancers-12-01515-t005){ref-type="table"}). This was confirmed by another multivariate analysis model built to take into account KCO, significant at univariate (*p* = 0.016) but not at multivariate analysis.

To note, among patients harboring PAD/AoD ratio \> 1, the occurrence of postoperative ARDS or IMV was not significantly different compared to other patients (*p* = 1.0 and *p* = 0.37, respectively).

Furthermore, NPAD predicted postoperative occurrence of re-do intubation (*p* = 0.014) or ARDS (*p* = 0.027) when the 5 patients with malignancy other than NSCLC were excluded.

Last, neither PAP systolic measure taken at echocardiography (*n* = 233) nor estimation of left ventricle ejection fraction predicted the occurrence of re-do intubation or ARDS.

Post-operative mortality was 25/294 (8.5%). Relations between patient and tumor-related factors with mortality are reported in [Table 4](#cancers-12-01515-t004){ref-type="table"}. At univariate analysis, older age (*p* = 0.00046), right side of pneumonectomy (*p* = 0.0062), lower ppoFEV1 (*p* = 0.047), and CCI \>5 (*p* = 0.000086) were significantly associated with postoperative mortality. The association of higher NPAD with postoperative mortality was close to significance at univariate analysis (*p* = 0.06) but reached significance (*p* = 0.026, OR 3.39 \[1.15--9.95\]) at multivariate analysis (model including age, side, ppoFEV1, CCI, and NPAD), together with right side of pneumonectomy (*p* = 0.0074, OR 4.11 \[1.46--11.56\]) and CCI \>5 (*p* = 0.0011, OR 5.56 \[1.99--15.54\]) ([Table 5](#cancers-12-01515-t005){ref-type="table"}).

3. Discussion {#sec3-cancers-12-01515}
=============

In the present paper we report evidence that NPAD is a strong and independent predictor of occurrence of post pneumonectomy respiratory failure and ARDS. It also independently predicted post-operative mortality.

In 1962 Rams et al. reported that intraoperative mean PAP was higher in pneumonectomy patients presenting catastrophic post-operative respiratory complications (on the average, 26 mmHg versus 22 mmHg) \[[@B16-cancers-12-01515]\]. Mean PAP measurement is based on right cardiac catheterization, an invasive and possibly morbid procedure which is not recommended in the routine pre-operative work-up of lung cancer possibly necessitating pneumonectomy. Extrapolation of mean PAP from systolic one measured at echocardiography remains matter of debate \[[@B20-cancers-12-01515],[@B21-cancers-12-01515]\]. Anyway, no experience exists in lung cancer patients and, a fortiori, in those requiring pneumonectomy.

In this series we assessed both crude and NPAD and found that normalized one was a much more reliable parameter. Although it has been reported---and confirmed by our findings---that PAD is dependent on BSA \[[@B22-cancers-12-01515]\], normalization of crude measure by this parameter has not been reported so far, in spite of quite common practice of normalizing AoDby BSA in vascular surgery studies \[[@B23-cancers-12-01515]\].

We also assessed PAD/AOD ratio and failed to find any correlation between this parameter and outcome. The PAD/AoD ratio \>1 has been reported to indicate pulmonary hypertension \[[@B22-cancers-12-01515]\] and is associated with COPD exacerbation \[[@B24-cancers-12-01515]\]. Probably, this parameter better identifies patent pulmonary hypertension more than subclinical one, which could be detected by increased NPAD. We hypothesize that, as pneumonectomy leads to non-negligible loss of global respiratory function and is associated with significant hemodynamic alteration with increase of the pulmonary blood flow to the remaining lung, in case of pre-existent subclinical pulmonary hypertension, this condition could favor the occurrence of postoperative respiratory failure and ARDS.

In this study, we identified right side of pneumonectomy as an independent risk factor of respiratory failure and mortality after pneumonectomy. For ARDS, significance at univariate analysis was lost at multivariate analysis. Several studies, including ours in a larger dataset, reported a higher postoperative rate of respiratory failure and ARDS after right-side pneumonectomy \[[@B2-cancers-12-01515],[@B9-cancers-12-01515],[@B15-cancers-12-01515],[@B25-cancers-12-01515]\]. We underlined that this could relate to multiple factors, including the more frequent predominance of the right lung in terms of perfusion and the higher postoperative PAP after right than left pneumonectomy \[[@B26-cancers-12-01515]\]. Preoperative work-up included lung perfusion scan in all patients and echocardiography in almost all. These noninvasive tests are sensitive enough to detect baseline mild pulmonary hypertension and to predict severe postpneumonectomy pulmonary hypertension, which has been reported to be associated with postpneumonectomy ARDS \[[@B27-cancers-12-01515]\]. Apart from preoperative ventilatory function, the adequacy of pulmonary vascular bed and circulation after pneumonectomy may be crucial to predict postoperative respiratory failure and ARDS. Fee and colleagues \[[@B28-cancers-12-01515]\] proposed preoperative assessment of pulmonary vascular resistance by right heart catheterization at rest and during exercise; they suggested that high pulmonary vascular resistance is a better predictor of mortality than simple pulmonary function tests, underlining a possible role of secondary pulmonary hypertension caused by a reduction in the pulmonary capillary bed as a determinant of post-pneumonectomy respiratory failure and ARDS.

We found that higher CCI (≥5) was independently associated with the three evaluated outcome measures. Comorbidities are known to be associated with a higher risk of postoperative respiratory complications \[[@B9-cancers-12-01515]\]. Postoperative pneumonia is the most frequent complication leading to respiratory failure; of note the occurrence of postpneumonectomy pneumonia is associated with comorbidities, suggesting that comorbidities may predispose to pneumonia, which in turn may evolve toward respiratory failure, ARDS, and death \[[@B15-cancers-12-01515],[@B16-cancers-12-01515],[@B17-cancers-12-01515],[@B18-cancers-12-01515],[@B19-cancers-12-01515],[@B20-cancers-12-01515],[@B21-cancers-12-01515],[@B22-cancers-12-01515],[@B23-cancers-12-01515],[@B24-cancers-12-01515],[@B25-cancers-12-01515]\]. Of note, comorbidities are also associated with a higher risk of postoperative bleeding and need for transfusion, which are well-known risk factors for ARDS.

Strengths and Limitations of the Study
--------------------------------------

A high number of consecutive patients undergoing pneumonectomy in a single institution, and whose pre-operative scan was available, were evaluated. To our knowledge assessment of PAD as a predictor of outcome in lung cancer patients requiring pneumonectomy has not been reported so far, except in our pilot study \[[@B19-cancers-12-01515]\]. Main limitation of the present study relies in its retrospective character despite the small number of patients with missing data. In our center, right catherization is not carried out routinely, but discussed on a case-by-case basis in case of patent pulmonary hypertension at echography. On the basis of our results, the idea of performing this invasive assessment of pulmonary pressure in patients with high NPAD (which otherwise reveals moderate increase in pulmonary arterial pressure) should probably be tested in the setting of prospective studies.

4. Materials and Methods {#sec4-cancers-12-01515}
========================

4.1. General Study Design {#sec4dot1-cancers-12-01515}
-------------------------

Clinical, laboratory, and pathological data from all consecutive patients who underwent pneumonectomy for malignancy at Paris Center University Hospital (Paris, France) between January 2007 and December 2015 were retrospectively retrieved. Among them, patients whose pre-thoracotomy computed thoracic and upper abdominal scan was available in the Picture Archive and Communication System (PACS) of the hospital were included in the present study. The patients represents a subset of population of previous studies on pneumonectomy outcomes \[[@B15-cancers-12-01515],[@B25-cancers-12-01515]\]. The research was conducted according to recommendations outlined in the Helsinki declaration as well as to French laws on Biomedical Research. An informed consent from all patients and IRB approval was obtained (CERC-SFCTCV-2015-11-4-13-16-16-AlMa/CPPHUPC).

4.2. Pre-Operative Investigations and Peri-Operative Care {#sec4dot2-cancers-12-01515}
---------------------------------------------------------

In all patients, pre-operative work-up included chest X-ray, fiber-optic bronchoscopy, thoracic and upper abdominal CT scan, as well as contrast-enhanced cerebral CT scan or MRI. PET scan was routinely performed. Neoadjuvant chemotherapy was administered in patients with pathologically confirmed N2-disease NSCLC, who were judged operable only in the presence of clinical response or stable disease.

Functional assessment included spirometry and perfusion lung scan, allowing calculation of ppoFEV1. Patients were considered operable without further investigation if ppoFEV1 was major to 40% and non-operable if ppoFEV1 was inferior to 30%. In intermediate cases decision of operability was taken on an individual basis taking into account results of DLCO determination and of an exercise test.

Pneumonectomy with radical nodal dissection was carried out through standard thoracotomy in all the cases. All the patients had intraoperative protective ventilation and fluid restriction. All were managed postoperatively in a specialized ICU and returned in the surgical ward on the 4th post-operative day if no complication occurred.

4.3. Collected Data {#sec4dot3-cancers-12-01515}
-------------------

Patients' characteristics, treatment procedures, and short-term outcomes were collected using a standardized case report form. We recorded: Age; sex; height; weight; medical history, including, tobacco consumption, ischemic heart disease and other co-morbidities; CCI; presence of symptoms; FEV1; FEV1/FVC ratio; ppoFEV1 (calculated on the basis of perfusion scan). We also collected histologic type and tumor stage which was reattributed according to the 7th TNM edition in NSCLC cases \[[@B29-cancers-12-01515]\].

We calculated for all the patient's body surface area according to the standard equation: BSA \[m^2^\] = weight \[kg\]^0.425^ × height \[cm\]^0.725^ × 71.84 \[m^2^/Kg × cm\].

4.4. CT Measurements {#sec4dot4-cancers-12-01515}
--------------------

Measure of diameters was carried out in a semiautomatic manner by using the measurement tool of the Carestream software (Carestream Health Inc., Rochester, NY, USA). Main PAD and AoD were measured on the same slice at level of pulmonary artery bifurcation, as reported by others \[[@B22-cancers-12-01515]\] and in our previous pilot study \[[@B19-cancers-12-01515]\]. PAD/AoD was then calculated. PAD was considered as crude value and normalized for BSA \[[@B19-cancers-12-01515]\].

4.5. Outcomes {#sec4dot5-cancers-12-01515}
-------------

Three main outcome measures were evaluated: Need of post-operative IMV (after successful extubation in the recovery room), occurrence of ARDS, and mortality. ARDS was defined as acute onset of hypoxemia, measured as PaO2/FIO2 ratio \<300 and infiltrate of the remaining lung on chest radiograph in the absence of clinical and echocardiographic findings of cardiac failure \[[@B30-cancers-12-01515]\]. Early mortality was defined as death occurring within the 30rd postoperative day or during the same hospitalization as pneumonectomy, even if beyond the 30rd postoperative day.

4.6. Data Analysis {#sec4dot6-cancers-12-01515}
------------------

Data processing and analysis were performed with the statistical Software system SEM (SILEX Developpment, Mirefleurs, France). Results were expressed as percentage, mean ±SD for normally distributed and median (interquartile range) for non-normally distributed quantitative variables.

Univariate analyses were performed to assess relationships with patients' characteristics and histological features, and correlations were assessed by the Spearman rank test for continuous variables. Mann--Whitney and Kruskal--Wallis tests were used to perform group comparisons as appropriate. Parameters showing correlations (*p* \< 0.1) with different outcome parameters at univariate analysis were entered in a backward logistic regression models to assess their independent value. A *p*-value of less than 0.05 was considered significant.

5. Conclusions {#sec5-cancers-12-01515}
==============

Normalized pulmonary artery diameter is a strong predictor of severe respiratory complications after pneumonectomy. In perspective, we could suggest that pulmonary artery measure should be integrated in the risk evaluation of patients requiring pneumonectomy; development of comprehensive prognostic index systems need to be developed in adequately designed studies.
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cancers-12-01515-t001_Table 1

###### 

Patients′ characteristics.

  --------------------------------------------------------------------------------------------------------
  Features                                                      Total Sample = 294
  ------------------------------------------------------------- ------------------------------------------
  Age: Years                                                    63.9 ± 9.9

  Gender: Men/Women                                             211 (71.8%)/83(28.2%)

  Current/Never Smokers (*n* = 291)                             267 (91.8%)/24 (8.2%)

  Cumulative tobacco consumption (Pack/Years) (*n* = 291)       40 (30--50)

  Right/Left side                                               135 (45.9%)/159 (54.1%)

  Weight (kg)                                                   71.84 ± 14.48

  Height (cm)                                                   169.3 ± 8.1

  BMI (kg/m^2^)                                                 24.98 ± 4.29; median 24

  Underweight \<18.5                                            18 (6.1%)

  Normal weight 18.5--25                                        137 (46.6%)

  Overweight 25.01--30                                          102 (34.7%)

  Obesity \>30                                                  37 (12.6%)

  BSA (m^2)^                                                    1.82 ± 0.19

  Diabetes Yes/No (*n* = 291)                                   24 (8.2%)/267 (91.8%)

  Hypertension Yes/No (*n* = 291)                               110 (37.8%)/181 (62.2%)

  Ischemic Heart Disease Yes/No (*n* = 291)                     61 (21.0%)/230 (79.0%)

  CCI (*n* = 291)                                               5.1 ±1.7; median 5.0

  Baseline Modified Borg Dyspnea Scale \>2 (*n* = 288) Yes/No   53 (18.4%)/235 (81.6%)

  FEV1 (% of predicted)                                         79.9 ± 17.1

  FEV1/FVC ratio (*n* = 285)                                    71.9 ± 13.2

  ppoFEV1                                                       50.56 ± 11.24

  Pattern of respiratory function (*n* = 285)\                  104 (36.5%)\
  Normal\                                                       118 (41.4%)\
  Obstructive\                                                  63 (22.1%)
  Restrictive                                                   

  KCO (% of predicted) (*n* = 132)                              78.13 ± 21.07

  PAD (mm)                                                      26.0 (24.0--28.0)

  NPAD (mm/m^2^)                                                14.4 ± 2.0 Median 14.0 (13.0--15.6)

  Ratio PAD/AoD                                                 0.8 ± 0.1

  NAC Yes/No (*n* = 291)                                        90(30.9%)/201(69.1%)

  NAR Yes/No (*n* = 291)                                        4 (1.4%)/287 (98.6%)

  NSCLC/other malignancies                                      289 (98.3%)/5 (1.7%)

  SqCLC/malignancies other than SqCLC                           146 (49.7%)/148 (50.3%)

  Pathologic stage I/II/IIIA/IIIB/IV (*n* = 282/289 NSCLC)      21 (7.4%)/71 (25.2%)/176 (62.4%)/14 (5%)
  --------------------------------------------------------------------------------------------------------

BMI: Body Mass Index; BSA: Body Surface Are; CCI Charlson Comorbidity Index; FEV1: Forced Expiratory Volume in 1 s; FVC: Forced Vital Capacity; ppoFEV1: postoperative Forced Expiratory Volume in 1 s; KCO: Coefficient of the lung for carbon monoxide; PAD: Pulmonary Artery Diameter, NPAD: Normalized Pulmonary Artery Diameter; AoD: Aorta Diameter; NAC: Neoadjuvant Chemotherapy; NAR: Neoadjuvant Radiotherapy; NSCLC: Non-Small Cell Lung Cancer; SqCLC: Squamous Cells Lung Cancer.

cancers-12-01515-t002_Table 2

###### 

Correlations between NPAD and PAD/aorta diameter (AoD) ratio with morphometric, clinical and laboratory variables.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Feature                                                          Normalized Pulmonary Artery Diameter   *p*             Ratio PAD/AoD   *p*            
  ---------------------------------------------------------------- -------------------------------------- --------------- --------------- -------------- --------
  Mean age                                                         61.48 ± 9.89                           64.70 ± 9.74    0.0049          r = −0.186     0.0015

  Men                                                              113 (53.6%)                            98 (46.4%)      0.052           0.79 ± 0.11    0.31

  Women                                                            34 (41.0%)                             49 (59.0%)      0.81 ± 0.11                    

  Smoke (*n* = 291)\                                               131 (49.1%)\                           136 (50.9%)\    0.21            0.79 ± 0.11\   0.71
  Current\                                                         15 (62.5%)                             9 (37.5%)                       0.80 ± 0.09    
  Never Smokers                                                                                                                                          

  Mean cumulative tobacco consumption (Pack/Years) (*n* = 291)     39.53 ± 24.84                          41.41 ± 22.13   0.39            r = −0.065     0.26

  Right side                                                       59 (43.7%)                             76 (56.3%)      0.047           0.81 ± 0.11    0.067

  Left side                                                        88 (55.4%)                             71 (44.6%)      0.78 ± 0.11                    

  Weight (kg)                                                      76.04 ± 13.96                          67.65 ± 13.76   0.00000021      r = 0.019      0.74

  Height (cm)                                                      171.4 ± 8.2                            167.3 ± 7.5     0.000081        r = 0.011      0.85

  BMI (kg/m^2^)                                                    25.87 ± 4.26                           24.09 ± 4.13    0.00024         r = 0.032      0.59

  Underweight                                                      7 (38.9%)                              11 (61.1%)      0.78            0.78 ± 0.11    0.77

  Normal weight                                                    58 (42.3%)                             79 (57.7%)      0.79 ± 0.11                    

  Overweight                                                       59 (57.8%)                             43 (42.2%)      0.80 ± 0.11                    

  Obesity                                                          23 (62.2%)                             14 (37.8%)      0.79 ± 0.11                    

  BSA (m^2^)                                                       1.88 ± 0.19                            1.76 ± 0.19     \<0.0000001     r = 0.012      0.84

  CCI                                                              4.89 ± 1.64                            5.34 ± 1.83     0.041           r = −0.120     0.040

  Baseline dyspnea---Modified Borg Dyspnea Scale ≥2 (*n* = 288)\   28 (52.8%)\                            25 (47.2%)\     0.57            0.80 ± 0.09\   0.56
  Yes\                                                             114 (48.5%)                            121 (51.5%)                     0.80 ± 0.11    
  No                                                                                                                                                     

  Mean FEV1 (% of predicted)                                       79.84 ± 16.02                          79.90 ± 18.10   0.97            r = −0.040     0.50

  Mean FEV1/FVC (*n* = 285)                                        72.31 ± 12.79                          71.55 ± 13.68   0.81            r = 0.022      0.72

  Pattern of respiratory function (*n* = 285)\                     60 (50.8%)\                            58 (49.2%)\     0.83            0.79 ± 0.12\   0.54
  Obstructive\                                                     51 (49.0%)\                            53 (51.0%)\                     0.79 ± 0.11\   
  Normal\                                                          31 (49.2%)                             32 (50.8%)                      0.80 ± 0.11    
  Restrictive                                                                                                                                            

  Mean ppoFEV1                                                     50.68 ± 11.20                          50.43 ± 11.29   0.88            r = −0.027     0.69

  NAC (*n* = 291)\                                                 46 (51.1%)\                            44 (48.9%)\     0.83            0.80 ± 0.11\   0.73
  Yes\                                                             100 (49.75%)                           101 (50.25%)                    0.79 ± 0.11    
  No                                                                                                                                                     

  NAR (*n* = 291)\                                                 2 (50%)\                               2 (50%)\        0.62            0.83 ± 0.04\   0.48
  Yes\                                                             144 (50.17%)                           143 (49.83%)                    0.79 ± 0.11    
  No                                                                                                                                                     

  Type of malignancy\                                              142 (49.1%)\                           147 (50.9%)\    0.07            0.80 ± 0.11\   0.76
  NSCLC\                                                           5 (100%)                               0 (0%)                          0.78 ± 0.11    
  Other malignancies                                                                                                                                     

  SqCLC                                                            72 (49.3%)                             74 (50.7%)      0.82            0.80 ± 0.12    0.28

  malignancies other than SqCLC                                    75 (50.7%)                             73 (49.3%)      0.80 ± 0.11                    

  Pathologic stage (*n* = 282/289 NSCLC)\                          46 (50.0%)\                            46 (50.0%)\     0.80            0.79 ± 0.11\   0.44
  I--II\                                                           92 (48.4%)                             98 (51.6%)                      0.80 ± 0.11    
  III--IV                                                                                                                                                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI: Body Mass Index; BSA: Body Surface Are; CCI Charlson Comorbidity Index; FEV1: Forced Expiratory Volume in 1 s; FVC: Forced Vital Capacity; KCO: Coefficient of the lung for carbon monoxide; ppoFEV1: postoperative Forced Expiratory Volume in 1 s; NAC: Neoadjuvant Chemotherapy; NAR: Neoadjuvant Radiotherapy; NSCLC: Non-Small Cell Lung Cancer; SqCLC: Squamous cells lung cancer; PAD: Pulmonary Artery Diameter, NPAD: Normalized Pulmonary Artery Diameter; AoD: Aorta Diameter.
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###### 

Correlations between patient's and tumor related factors with occurrence of respiratory failure requiring intubation and ARDS.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Feature                                                          Need of Mechanical Ventilation   ARDS                                                         
  ---------------------------------------------------------------- -------------------------------- --------------- ------------ --------------- --------------- --------
  Mean age                                                         66.26 ± 9.53                     62.50 ± 9.91    0.028        67.43 ± 8.78    62.60 ± 9.95    0.020

  Men                                                              38 (18.0%)                       173 (82.0%)     0.075        24 (11.4%)      187 (88.6%)     0.29

  Women                                                            8 (9.64%)                        75 (90.36%)     6 (7.2%)     77 (92.8%)                      

  Smoke (*n* = 291)\                                               43 (16.1%)\                      224 (83.9%)\    0.86         28 (10.5%)\     239 (89.5%)\    0.99
  Current\                                                         3 (12.5%)                        21 (87.5%)                   2 (8.3%)        22 (91.7%)      
  Never Smokers                                                                                                                                                  

  Mean cumulative tobacco consumption (Pack/Years) (*n* = 291)     41.96 ± 21.80                    40.19 ± 23.85   0.67         43.53 ± 22.22   40.12 ± 23.67   0.41

  Right side                                                       29 (21.5%)                       106 (78.5%)     0.011        19 (14.1%)      116 (85.9%)     0.043

  Left side                                                        17 (10.7%)                       142 (89.3%)     11 (6.9%)    148 (93.1%)                     

  Weight (Kg)                                                      71.22 ± 14.94                    71.96 ± 14.39   0.73         70.27 ± 14.18   72.02 ± 14.51   0.53

  Height (cm)                                                      170.61 ± 8.80                    169.1 ± 8.0     0.28         168.1 ± 6.6     169.4 ± 8.3     0.39

  BMI (kg/m^2^)                                                    24.45 ± 4.64                     25.08 ± 4.21    0.39         24.86 ± 4.76    24.99 ± 4.23    0.87

  BSA (m^2^)                                                       1.82 ± 0.20                      1.817 ± 0.196   0.92         1.79 ± 0.18     1.821 ± 0.199   0.44

  CCI                                                              6.20 ± 1.92                      4.90 ± 1.64     0.00032      5.93 ± 1.57     5.02 ± 1.75     0.0043

  Baseline dyspnea---Modified Borg Dyspnea Scale \>2 (*n*= 288)\   8 (15.1%)\                       45 (84.9%)\     0.97         5 (9.4%)\       48 (9.6%)\      0.86
  Yes\                                                             36 (15.3%)                       199 (84.7%)                  24 (10.2%)      211 (89.8%)     
  No                                                                                                                                                             

  Mean FEV1 (% of predicted)                                       76.22 ± 17.11                    80.55 ± 17.00   0.18         78.53 ± 14.78   80.02 ± 17.33   0.64

  Mean FEV1/FVC (*n* = 285)                                        73.41 ± 15.22                    71.66 ± 12.84   0.58         75.29 ± 13.02   71.56 ± 13.22   0.24

  Pattern of respiratory function (*n* = 285)\                     18 (15.3%)\                      100 (84.7%)\    0.18         10 (8.5%)\      108 (91.5%)\    0.098
  Obstructive\                                                     12 (11.5%)\                      92 (88.5%)\                  8 (7.7%)\       96 (92.3%)\     
  Normal\                                                          14 (22.2%)                       49 (77.8%)                   10 (15.9%)      53 (84.1%)      
  Restrictive                                                                                                                                                    

  Mean KCO (*n* = 132) (% of predicted)                            70.25 ± 19.32                    79.88 ± 21.05   0.041        65.43 ± 15.00   79.64 ± 21.18   0.016

  Mean ppoFEV1                                                     47.83 ± 9.81                     51.07 ± 11.42   0.12         49.08 ± 10.70   50.73 ± 11.29   0.54

  NAC (*n* = 291)\                                                 10 (11.1%)\                      80 (88.9%)\     0.14         5 (5.6%)\       85 (94.4%)\     0.074
  Yes\                                                             36 (17.9%)                       165 (82.1%)                  25 (12.4%)      176 (87.6%)     
  No                                                                                                                                                             

  NAR (*n* = 291)\                                                 0 (0.0%)\                        4 (100.0%)\     0.86         0 (0.0%)\       4 (100.0%)\     0.88
  Yes\                                                             46 (16.0%)                       241 (84.0%)                  30 (10.4%)      257 (89.6%)     
  No                                                                                                                                                             

  Type of malignancy\                                              46 (15.9%)\                      243 (84.1%)\    0.73         30 (10.4%)\     259 (89.6%)\    0.99
  NSCLC\                                                           0 (0.0%)                         5 (100.0%)                   0 (0.0%)        5 (100.0%)      
  Other malignancies                                                                                                                                             

  SqCLC                                                            25 (17.1%)                       121 (82.9%)     0.49         15 (10.3%)      131 (89.7%)     0.97

  Malignancies other than SqCLC                                    21 (14.2%)                       127 (85.8%)     15 (10.1%)   133 (89.9%)                     

  Pathologic stage (*n* = 282/289 NSCLC)\                          18 (19.6%)\                      74 (80.4%)\     0.30         12 (13.4%)\     80 (89.9%)\     0.36
  I--II\                                                           28 (14.7%)                       162 (85.3%)                  18 (9.47%)      172 (90.5%)     
  III--IV                                                                                                                                                        

  PAD (mm)                                                         26.74 ± 3.70                     25.80 ± 3.34    0.22         26.37 ± 3.37    25.90 ± 3.42    0.60

  NPAD (≥median)\                                                  31 (21.1%)\                      116 (78.9%)\    0.010        21 (14.3%)\     126 (85.7%)\    0.021
  Yes\                                                             15 (10.2%)                       132 (89.8%)                  9 (6.1%)        138 (93.9%)     
  No                                                                                                                                                             

  PAD/AoD ratio                                                    0.82 ± 0.13                      0.79 ± 0.11     0.18         0.80 ± 0.12     0.79 ± 0.11     0.85
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI: Body Mass Index; BSA: Body Surface Are; CCI Charlson Comorbidity Index; FEV1: Forced Expiratory Volume in 1 s; FVC: Forced Vital Capacity; KCO: Coefficient of the lung for carbon monoxide; ppoFEV1: postoperative Forced Expiratory Volume in 1 s; NAC: Neoadjuvant Chemotherapy; NAR: Neoadjuvant Radiotherapy; NSCLC: Non-Small Cell Lung Cancer; SqCLC: Squamous cells lung cancer; PAD: Pulmonary Artery Diameter, NPAD: Normalized Pulmonary Artery Diameter; AoD: Aorta Diameter.
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###### 

Correlations between patient's and tumor related factors with postoperative mortality.

  -----------------------------------------------------------------------------------------------------------------------
  Feature                                                           30-Day Mortality                           
  ----------------------------------------------------------------- ------------------ ----------------------- ----------
  Mean age                                                          69.76 ± 7.47       62.47 ± 9.92            0.00046

  Men                                                               18 (8.5%)          193 (91.5%)             0.98

  Women                                                             7 (91.6%)          76 (8.4%)               

  Smoke (*n* = 291)\                                                22 (8.3%)\         245 (91.7%)\            0.74
  Current\                                                          3 (12.5%)          21 (87.5%)              
  Never Smokers                                                                                                

  Mean cumulative tobacco consumption (Pack/Years) (*n* = 291)      41.08 ± 23.73      40.41 ± 23.53           0.77

  Right side                                                        18 (13.3%)         117 (86.7%)             0.0062

  Left side                                                         7 (4.4%)           152 (95.6%)             

  Weight (kg)                                                       71.92 ± 15.45      71.84 ± 14.39           0.93

  Height (cm)                                                       167.70 ± 7.10      169.50 ± 8.20           0.31

  BMI (kg/m^2^)                                                     25.53 ± 4.98       24.93 ± 4.21            0.51

  BSA (m^2^)                                                        1.80 ± 0.20        1.80 ± 0.19             0.73

  CCI                                                               6.41 ± 1.81        4.98 ± 1.69             0.000086

  Baseline dyspnea---Modified Borg Dyspnea Scale \>2 (*n* = 288)\   4 (7.6%)\          49 (92.4%)\             0.99
  Yes\                                                              21 (8.9%)          214 (91.1%)             
  No                                                                                                           

  Mean FEV1 (% of predicted)                                        78.24 ± 14.78      80.02 ± 17.28           0.65

  Mean FEV1/FVC (*n* = 285)                                         72.13 ± 15.16      71.91 ± 13.07           0.60

  Pattern of respiratory function (*n* = 285)\                      12 (10.2%)\        106 (89.8%)\            0.042
  Obstructive\                                                      3 (2.9%)\          101 (97.1%)\            
  Normal\                                                           8 (12.7%)          55 (87.3%)              
  Restrictive                                                                                                  

  Mean KCO (*n* = 132) (% of predicted)                             73.09 ± 22.01      78.59 ± 20.93           0.42

  Mean ppoFEV1                                                      45.86 ± 8.55       51.06 ± 11.38           0.047

  NAR (291)\                                                        0 (0.0%)\          4 (100.0%)\             0.78
  Yes\                                                              25 (89.7%)         262 (91.3%)             
  No                                                                                                           

  NAC (291)\                                                        4 (4.4%)\          86 (95.6%)\             0.091
  Yes\                                                              21 (10.5%)         180 (89.5%)             
  No                                                                                                           

  Type of malignancy\                                               25 (8.5%)\         264 (91.5%)\            0.90
  NSCLC\                                                            0 (0.0%)           5 (100.0%)              
  Other malignancies                                                                                           

  SqCLC                                                             12 (8.2%)          134 (91.8%)             0.86

  Malignancies other than SqCLC                                     13 (8.8%)          135 (91.2%)             

  Pathologic stage (*n* = 282/289 NSCLC)\                           11 (12.0%)\        81 (88.0%)\             0.20
  I--II\                                                            14 (7.4%)          176 (92.6%)             
  III--IV                                                                                                      

  PAD (mm)                                                          26.60 ± 3.60       25.88 ± 3.39            0.38

  NPAD (≥median)\                                                   8 (5.4%)\          139(94.6%) 130(88.4%)   0.06
  Yes\                                                              17 (11.6%)                                 
  No                                                                                                           

  PAD/AoD ratio                                                     0.808 ± 0.141      0.793 ± 0.107           0.67
  -----------------------------------------------------------------------------------------------------------------------

BMI: Body Mass Index; BSA: Body Surface Are; CCI Charlson Comorbidity Index; FEV1: Forced Expiratory Volume in 1 s; FVC: Forced Vital Capacity; KCO: Coefficient of the lung for carbon monoxide; ppoFEV1: postoperative Forced Expiratory Volume in 1 s; NAC: Neoadjuvant Chemotherapy; NAR: Neoadjuvant Radiotherapy; NSCLC: Non-Small Cell Lung Cancer; SqCLC: Squamous cells lung cancer; PAD: Pulmonary Artery Diameter, NPAD: Normalized Pulmonary Artery Diameter; AoD: Aorta Diameter.
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###### 

Multivariable analysis.

  Feature               OR         IC 95%        *p*           
  --------------------- ---------- ------------- ------------- --------
  **IMV**               CCI \> 5   3.8           1.76--822     0.0009
  Right pneumonectomy   2.37       1.20--4.71    0.013         
  NPAD \> 14 mm/m^2^    2.16       1.08--4.33    0.029         
  **ARDS**              CCI \> 5   2.55          1.17--5.59    0.018
  NPAD \> 14 mm/m^2^    2.52       1.10--5.77    0.028         
  **DEATH**             CCI \> 5   5.56          1.99--15.54   0.0011
  Right pneumonectomy   4.11       1.46--11.56   0.0074        
  NPAD \> 14 mm/m^2^    3.39       1.15--9.95    0.026         

IMV: Invasive Mechanical Ventilation, CCI Charlson Comorbidity Index; NPAD: Normalized Pulmonary Artery Diameter; ARDS: Acute Respiratory Distress Syndrome.

[^1]: These authors had equal contribution.
